"I Didn't Really Understand It, I Just Thought It'd Help": Exploring the Motivations, Understandings and Experiences of Patients with Advanced Lung Cancer Participating in a Non-placebo Clinical IMP Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2016 Jul 22

PMID 27439472

Citations 17

Authors

Emily Harrop

Simon Noble

Michelle Edwards

Stephanie Sivell

Barbara Moore

Annmarie Nelson

Affiliations

Soon will be listed here.

Abstract

Background: Few studies have explored in depth the experiences of patients with advanced cancer who are participating in clinical investigational medicinal product trials. However, integrated qualitative studies in such trials are needed to enable a broader evaluation of patient experiences in the trial, with important ethical and practical implications for the design and conduct of similar trials and treatment regimes in the future.

Methods: Ten participants were recruited from the control and intervention arms of FRAGMATIC: a non-placebo trial for patients with advanced lung cancer. Participants were interviewed at up to three time points during their time in the trial. Interviews were analysed using Interpretive Phenomenological Analysis.

Results: Patients were motivated to join the trial out of hope of medical benefit and altruism. Understanding of randomisation was mixed and in some cases poor, as was appreciation of trial purpose and equipoise. The trial was acceptable to and evaluated positively by most participants; participants receiving the intervention focused on the potential treatment benefits they hoped they would receive, whilst participants in the control arm found alternative reasons, such as altruism, personal fulfilment and positive attention, to commit to and perceive benefits from the trial. However, whilst experiences were generally very positive, poor understanding, limited engagement with trial information and focus on treatment benefits amongst some participants give cause for concern.

Conclusions: By exploring longitudinally the psychological, emotional and cognitive domains of trial participation, we consider potential harms and benefits of participation in non-placebo trials amongst patients with advanced lung cancer and identify several implications for future research with and care for patients with advanced cancer.

Trial Registration: ISRCTN80812769 . Registered on 8 July 2005.

Citing Articles

A qualitative study exploring participants' experiences of the SCOPE2 trial: chemoradiotherapy dose escalation in oesophageal cancer.

Holland-Hart D, Longo M, Bridges S, Nixon L, Hawkins M, Crosby T Trials. 2025; 26(1):70.

PMID: 40012034 PMC: 11863524. DOI: 10.1186/s13063-025-08768-z.

Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials.

Henley M, DeCotiis G, FitzGibbon H, Singhi E Future Oncol. 2024; 21(1):11-14.

PMID: 39692566 PMC: 11789468. DOI: 10.1080/14796694.2024.2433411.

Trusting relationships between patients with non-curative cancer and healthcare professionals create ethical obstacles for informed consent in clinical trials: a grounded theory study.

Murphy M, McCaughan E, Thompson G, Carson M, Hanna J, Donovan M BMC Palliat Care. 2023; 22(1):85.

PMID: 37393250 PMC: 10315048. DOI: 10.1186/s12904-023-01204-6.

"What I wanted to do was build myself back up and prepare": qualitative findings from the PERCEPT trial of prehabilitation during autologous stem cell transplantation in myeloma.

McCourt O, Fisher A, Land J, Ramdharry G, Roberts A, Bekris G BMC Cancer. 2023; 23(1):348.

PMID: 37069548 PMC: 10107576. DOI: 10.1186/s12885-023-10799-1.

Hope and meaning-making in phase 1 oncology trials: a systematic review and thematic synthesis of qualitative evidence on patient-participant experiences.

Escritt K, Mann M, Nelson A, Harrop E Trials. 2022; 23(1):409.

PMID: 35578308 PMC: 9112562. DOI: 10.1186/s13063-022-06306-9.

References

Snowdon C, Elbourne D, Garcia J . Zelen randomization: attitudes of parents participating in a neonatal clinical trial. Control Clin Trials. 1999; 20(2):149-71. DOI: 10.1016/s0197-2456(98)00049-x. View

Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T . Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be.... BMJ. 2002; 325(7367):766-70. PMC: 1124277. DOI: 10.1136/bmj.325.7367.766. View

Sulmasy D, Astrow A, He M, Seils D, Meropol N, Micco E . The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer. 2010; 116(15):3702-11. PMC: 3644988. DOI: 10.1002/cncr.25201. View

Lilford R . Ethics of clinical trials from a bayesian and decision analytic perspective: whose equipoise is it anyway?. BMJ. 2003; 326(7396):980-1. PMC: 1125887. DOI: 10.1136/bmj.326.7396.980. View

Snowdon C, Elbourne D, Garcia J . "It was a snap decision": parental and professional perspectives on the speed of decisions about participation in perinatal randomised controlled trials. Soc Sci Med. 2005; 62(9):2279-90. DOI: 10.1016/j.socscimed.2005.10.008. View

Sivell S, Prout H, Hopewell-Kelly N, Baillie J, Byrne A, Edwards M . Considerations and recommendations for conducting qualitative research interviews with palliative and end-of-life care patients in the home setting: a consensus paper. BMJ Support Palliat Care. 2015; 9(1):e14. PMC: 6579488. DOI: 10.1136/bmjspcare-2015-000892. View

Moynihan C, Lewis R, Hall E, Jones E, Birtle A, Huddart R . The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE,.... Trials. 2012; 13:228. PMC: 3554516. DOI: 10.1186/1745-6215-13-228. View

Appelbaum P, Roth L, Lidz C, Benson P, Winslade W . False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987; 17(2):20-4. View

Braunholtz D, Edwards S, Lilford R . Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol. 2001; 54(3):217-24. DOI: 10.1016/s0895-4356(00)00305-x. View

10.

Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan J . Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials. 2011; 12:78. PMC: 3068963. DOI: 10.1186/1745-6215-12-78. View

11.

Addington-Hall J . Research sensitivities to palliative care patients. Eur J Cancer Care (Engl). 2002; 11(3):220-4. DOI: 10.1046/j.1365-2354.2002.00343.x. View

12.

Cox K, Avis M . Ethical and practical problems of early anti-cancer drug trials: a review of the literature. Eur J Cancer Care (Engl). 1996; 5(2):90-5. DOI: 10.1111/j.1365-2354.1996.tb00214.x. View

13.

Mills N, Donovan J, Smith M, Jacoby A, Neal D, Hamdy F . Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials. 2003; 24(3):272-82. DOI: 10.1016/s0197-2456(03)00020-5. View

14.

Griffiths G, Burns S, Noble S, Macbeth F, Cohen D, Maughan T . FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer. 2009; 9:355. PMC: 2761945. DOI: 10.1186/1471-2407-9-355. View

15.

Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N . QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials. 2013; 14:325. PMC: 3856513. DOI: 10.1186/1745-6215-14-325. View

16.

Dean R, McClement S . Palliative care research: methodological and ethical challenges. Int J Palliat Nurs. 2002; 8(8):376-80. DOI: 10.12968/ijpn.2002.8.8.10681. View

17.

Harrop E, Kelly J, Griffiths G, Casbard A, Nelson A . Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy). Trials. 2016; 17:35. PMC: 4719666. DOI: 10.1186/s13063-016-1173-z. View

18.

Adamson D, Blazeby J, Nelson A, Hurt C, Nixon L, Fitzgibbon J . Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials. 2014; 15:402. PMC: 4223756. DOI: 10.1186/1745-6215-15-402. View

19.

Levinson W, Kao A, Kuby A, Thisted R . Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med. 2005; 20(6):531-5. PMC: 1490136. DOI: 10.1111/j.1525-1497.2005.04101.x. View

20.

Kohara I, Inoue T . Searching for a way to live to the end: decision-making process in patients considering participation in cancer phase I clinical trials. Oncol Nurs Forum. 2010; 37(2):E124-32. DOI: 10.1188/10.ONF.E124-E132. View